Locally Advanced Rectal Cancer
Conditions
Brief summary
The introduction of total mesorectal excision (TME) and the progress of neoadjuvant chemoradiotherapy has significantly reduced the risk of local recurrence in locally advanced rectal cancer. However, systemic recurrence rate is not being improved and that is considered as the cause of unsatisfactory overall survival of patients with rectal cancer. Relatively higher systemic relapse rate than local recurrence rate is probably due to the insufficient control of systemic micrometastasis during adjuvant chemotherapy. The efficacy of adjuvant combination cytotoxic chemotherapy after surgery in treatment of rectal cancer remains controversial. In addition, preoperative radiotherapy increases surgical complication such as anastomosis site leakage and radiotherapy itself worsen sexual and urinary function and bowel habit which result in aggravation of the quality of life. Furthermore the preoperative chemoradiotherapy upto 3 months not only extends treatment period but increases cost of care. To reduce the possibility of overtreatment, it is needed to confirm that the preoperative chemoradiotherapy is absolutely necessary to locally advanced rectal cancer patients with safe circumferential margin (CRM) resected curatively by standardized TME operation. In this study, investigators aim to evaluate the efficacy of adjuvant FOLFOX chemotherapy after TME without preoperative chemoradiotherapy in patients with locally advanced rectal cancer having spared CRM are not inferior to that of current standard treatment.
Interventions
DRUGArm A : standard neoadjuvant chemoradiotherapy group
radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle
DRUGArm B : adjuvant FOLFOX group
FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed adenocarcinoma of the rectum below 10 cm from the anal verge 2. Locally advanced rectal cancer (T3N0 or T1-3N+) 3. Age: 19-80 years old. 4. Without evidence of distant metastasis including paraortic lymph node, common & external iliac lymph node metastasis 5. MRI scan confirmed more than 2 mm circumferential margin 6. ECOG(Eastern Cooperative Oncology Group) performance status 0-2 7. preoperative ASA class I-III 8. No prior systemic treatment for rectal cancer (i.e. chemotherapy or immunotherapy) 9. No history of regional radiation treatment in the pelvic cavity 10. Adequate hematologic function: ANC(absolute neutrophil count) ≥ 1.5×109/L，Platelet ≥ 100×109/L, Adequate renal function: Cr ≤ 1.5×ULN or Glomerular filtration rate (Ccr calculated by Cockcroft formula) ≥ 50 ml/min, Adequate hepatic function: ALT(Alanine aminotransferase)/AST(aspartate aminotransferase) ≤ 2.5×ULN, Total bilirubin ≤ 1.5×ULN 11. Patients must be willing and able to comply with the protocol duration of the study 12. Signed informed consent
Exclusion criteria
1. Malignancy of the rectum other than adenocarcinoma or adenocarcinoma developed from inflammatory bowel disease 2. Suspicious distant metastasis 3. Patients with peripheral neuropathy ≥ NCI CTC(common terminology criteria) grade 1 4. Uncontrolled and significant cardiovascular disease (i.e. NYHA(New York Heart Association) class III or IV heart failure, myocardial infarction within the past 6 months, uncontrolled angina pectoris) 5. Uncontrolled active infection or serious concomitant systemic disorders incompatible with the study 6. Other co-existing malignancy or malignancy within the past 5 years, with the exception of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin 7. Patients requiring immunosuppressive treatment who received organ transplantation 8. Uncontrolled epilepsy and psychiatric disease 9. Pregnant or lactating patient 10. Females with a positive or no pregnancy test unless childbearing potential can be otherwise excluded (amenorrheic for at least 2 years,hysterectomy or oophorectomy) 11. Patients receiving a concomitant treatment with drugs interacting with 5-Fluorouracil or oxaliplatin such as flucytosine, phenytoin, or warfarin 12. Prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-Fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiency. 13. Known hypersensitivity to platinum-based drugs, leucovorin or capecitabine 14. Patients taking sorivudine or brivudine 15. Patients taking tegafur, gimeracil, oteracil potassium complex or stopped the medication within 7days before. 16. Patients who have hereditary disease like as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, etc. 17. Participant in any clinical trial within 4 weeks before initiation of the study 18. Treatment with bevacizumab, cetuximab, oxaliplatin or irinotecan before screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease free survival (DFS) | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS) | 3 years and 5 years |
| Local recurrence rate | 3 years and 5 years |
| Disease free survival (DFS) | 5 years |
| Total score for function of urination (IPSS) and defecation (Wexner's score) | 1 month and 6 months after surgery |
| Evaluation for rate of various events after surgery | 14 days after surgery |
| Systemic recurrence rate | 3 years and 5 years |
Countries
South Korea
Outcome results
None listed